spacer
home > pmps > winter 2001 > pharmaceutical supply chains - the developing role of it
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Pharmaceutical Supply Chains - The Developing Role of IT

In the constantly changing environment of pharmaceutical supply and value chains, what must we now demand of the supporting IT systems and IT departments in order to ensure their validity, focus and ability to realise their value-adding potential?

To analyse and understand this question, we must first look at the changing nature of the industry over recent years. We need to understand how supply chain services - such as primary and secondary procurement for manufacturing and proactive utilisation of information transferred to and from sales and marketing functions - have evolved. We can then look at the potential for pharmaceutical supply chain development in the future, particularly with the advent of collaborative commerce initiatives.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ray Dales and Melvyn Barnes of SchlumbergerSema Ray Dales is a Manufacturing and Supply Chain Professional with over 14 years' experience in the pharmaceutical industry. For the last six years, he has provided consultancy services to manufacturing industries, specifically in the areas of process improvement, the management of change, and supply chain development, particularly the opportunities offered by e-business initiatives.
Melvyn Barnes is an IT Professional and has been a Consultant with SchlumbergerSema for three years, specialising in the design, development and introduction of innovative IT strategies. He has over 25 years' experience of systems integration and IS strategy in the batch process manufacturing and pharmaceutical industries.

spacer
Ray Dales
spacer
spacer
spacer
Melvyn Barnes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement